LNCaP clone FGCHomo sapiens (Human)Cancer cell line
Also known as: LNCaP Fast Growing Colony, LNCaP-ATCC, LNCAPCLONEFGC, LNCaP FGC, LNCaP-FGC, LNCaP.FGC, LNCaP-Clone-FGC, LNCaP.FCG (Occasionally.)
Quick Overview
Human prostate cancer cell line used in cancer research, known for androgen independence and metastatic potential.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1379 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Left supraclavicular lymph node[UBERON:UBERON_8480056] |
Donor Information
| Age | 50 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Prostate carcinoma |
|---|---|
| Lineage | Prostate |
| Subtype | Prostate Adenocarcinoma |
| OncoTree Code | PRAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000977_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | PTEN | p.Lys6Argfs*4 (c.17_18delAA) | Unspecified | - | from parent cell line LNCaP clone FGC |
| MutationSimple | PIK3R1 | p.Arg639Ter (c.1915C>T) | Heterozygous | - | from parent cell line LNCaP clone FGC |
| MutationSimple | MEN1 | p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A) | Heterozygous | - | from parent cell line LNCaP clone FGC |
| MutationSimple | AR | p.Thr878Ala (c.2632A>G) | Hemizygous | - | from parent cell line LNCaP clone FGC |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
Paschal B.M.
BMC Cancer 18:960.1-960.20(2018).
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Gregory-Evans C.Y., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Oncotarget 8:18949-18967(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Dynamic DNA methylation across diverse human cell lines and tissues.
Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Genome Res. 23:555-567(2013).
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
Dehm S.M.
Cancer Res. 73:483-489(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.
Vasicek T.J., Hood L.E.
Cancer Res. 65:3081-3091(2005).
Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.
Gustavsson H., Welen K., Damber J.-E.
Prostate 62:364-373(2005).
Human prostate cancer cell lines.";
Russell P.J., Kingsley E.A.
Methods Mol. Med. 81:21-39(2003).
The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.
Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.
Cancer Genet. Cytogenet. 124:112-121(2001).
Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines.
Hagemeijer A.
Urol. Res. 27:3-8(1999).
p53 oncogene mutations in three human prostate cancer cell lines.";
Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.
Prostate 23:123-134(1993).